Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Market movers: Strategy, Bitmine, Tiziana Life Sciences...

Expion Energy (NASDAQ:XPON) said it closed the initial tranche of a private placement raising $9 million, with the potential for an additional $91 million from the same group of investors, as the company moves to fund its newly acquired oil and gas exploration assets in Eastern Louisiana.

Shares of the company, formerly known as Expion360, jumped 97% in afternoon trading.

Read more

Bitmine Immersion (NASDAQ:IMMR) Technologies (NYSE:BMNR) shares rose more than 7% on Monday after the company disclosed a holdings update showing total crypto and "moonshot" investments valued at $14.9 billion as of August 24, 2026.

The company said it has staked more than 5 million ETH, with holdings of 5,847,611 ETH valued at $2,440 per token, according to Coinbase pricing cited by the company. Bitmine also holds 210 Bitcoin.

Read more

MicroStrategy Incorporated (NASDAQ:MSTR) (Strategy) shares climbed 3.5% Monday after the bitcoin-focused firm completed a large at-the-market equity offering, raising roughly $2.01 billion in net proceeds through the sale of more than 18.2 million shares.

The capital raise strengthens Strategy's liquid reserves without requiring the company to sell any of its underlying cryptocurrency holdings.

Read more

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday.

The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” is scheduled for 4:30 pm to 6:30 pm Eastern Time during the Scientific Poster Session.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK